What is the recommended duration of systemic hormone therapy for vasomotor symptoms?

What is the recommended duration of systemic hormone therapy for vasomotor symptoms?

• A. 1-2 years
• B. 3-5 years
• C. 8-10 years
• D. Indefinite until symptoms resolve

Answer: (B)

Systemic hormone therapy is chosen for vasomotor symptoms to provide effective relief, but its use is limited by safety concerns that accumulate with time. The goal is to use the lowest dose for the shortest duration that controls symptoms. Clinically, three to five years is the commonly recommended window. After this period, the benefits and risks should be reassessed—breast cancer risk with combined estrogen-progestin, endometrial risk with estrogen alone in women with a uterus, and cardiovascular or thromboembolic risks—so that decisions can be made on stopping, continuing with careful monitoring, or switching to non-hormonal options. Shorter durations like one to two years may not fully address symptoms for many, while longer use (eight to ten years or indefinite) increases cumulative risk. The key idea is to balance effective relief with ongoing safety, tailoring the plan to the individual’s risk factors and symptom burden.

Systemic hormone therapy is chosen for vasomotor symptoms to provide effective relief, but its use is limited by safety concerns that accumulate with time. The goal is to use the lowest dose for the shortest duration that controls symptoms. Clinically, three to five years is the commonly recommended window. After this period, the benefits and risks should be reassessed—breast cancer risk with combined estrogen-progestin, endometrial risk with estrogen alone in women with a uterus, and cardiovascular or thromboembolic risks—so that decisions can be made on stopping, continuing with careful monitoring, or switching to non-hormonal options. Shorter durations like one to two years may not fully address symptoms for many, while longer use (eight to ten years or indefinite) increases cumulative risk. The key idea is to balance effective relief with ongoing safety, tailoring the plan to the individual’s risk factors and symptom burden.